Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is elevated cardiovascular risk a class effect of cyclo-oxygenase 2 inhibitors?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 532–533 (2006)Cite this article

boxed-textAndersohn F et al. (2006) Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 113: 1950–1957

These data support the view that higher doses of all COX2 inhibitors can increase cardiovascular risk and that a single mechanism is probably involved

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bresalier RS et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102

    Article  CAS  Google Scholar 

  2. Solomon SD et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  CAS  Google Scholar 

  3. Nussmeier NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. associate professor of Medicine at Harvard Medical School and the Director of Noninvasive Cardiology at the Brigham and Women's Hospital, Boston, MA, USA

    Scott D Solomon

Authors
  1. Scott D Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott D Solomon.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solomon, S. Is elevated cardiovascular risk a class effect of cyclo-oxygenase 2 inhibitors?. Nat Rev Cardiol 3, 532–533 (2006). https://doi.org/10.1038/ncpcardio0680

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0680

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing